Vancomycin
This powerful glycopeptide antibiotic is used intravenously to treat serious bacterial infections caused by gram-positive organisms, including methicillin-resistant Staphylococcus aureus (MRSA), and is taken orally specifically to treat Clostridioides difficile (C. diff) colitis. It is typically reserved for infections resistant to other antibiotics due to concerns about resistance. Blood levels, kidney function, and hearing must be carefully monitored during intravenous treatment.
分子量
1449.2500 g/mol
LogP
-2.60
TPSA
530.00 Ų
リピンスキーの五則
不適合
治療領域
薬物分類
作用機序
Glycopeptide antibiotic inhibiting cell wall synthesis by binding D-Ala-D-Ala terminus of peptidoglycan precursors.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Glycopeptide antibiotic inhibiting cell wall synthesis by binding D-Ala-D-Ala terminus of peptidoglycan precursors.
2D構造
Cite this structure
Embed this structure
SMILES
CN[C@H](CC(C)C)C(=O)N[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H]2C(=O)N[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)O)c4cc(O)cc(O)c4-c4cc3ccc4O)[C@H](O)c3ccc(c(Cl)c3)Oc3cc2cc(c3O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O[C@H]2C[C@](C)(N)[C@H](O)[C@H](C)O2)Oc2ccc(cc2Cl)[C@H]1O
InChI
InChI=1S/C66H75Cl2N9O24/c1-23(2)12-34(71-5)58(88)76-49-51(83)26-7-10-38(32(67)14-26)97-40-16-28-17-41(55(40)101-65-56(54(86)53(85)42(22-78)99-65)100-44-21-66(4,70)57(87)24(3)96-44)98-39-11-8-27(15-33(39)68)52(84)50-63(93)75-48(64(94)95)31-18-29(79)19-37(81)45(31)30-13-25(6-9-36(30)80)46(60(90)77-50)74-61(91)47(28)73-59(89)35(20-43(69)82)72-62(49)92/h6-11,13-19,23-24,34-35,42,44,46-54,56-57,65,71,78-81,83-87H,12,20-22,70H2,1-5H3,(H2,69,82)(H,72,92)(H,73,89)(H,74,91)(H,75,93)(H,76,88)(H,77,90)(H,94,95)/t24-,34+,35-,42+,44-,46+,47+,48-,49+,50-,51+,52+,53+,54-,56+,57+,65-,66-/m0/s1
Molecular Formula
C66H75Cl2N9O24
HBD / HBA
19 / 26
回転可能結合数
13
重原子数
101
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
よくある質問
This powerful glycopeptide antibiotic is used intravenously to treat serious bacterial infections caused by gram-positive organisms, including methicillin-resistant Staphylococcus aureus (MRSA), and is taken orally specifically to treat Clostridioides difficile (C. diff) colitis. It is typically reserved for infections resistant to other antibiotics due to concerns about resistance. Blood levels, kidney function, and hearing must be carefully monitored during intravenous treatment.
Glycopeptide antibiotic inhibiting cell wall synthesis by binding D-Ala-D-Ala terminus of peptidoglycan precursors.
Key pharmacokinetic parameters for Vancomycin: Half-life: 4-6 hours.
Yes, Vancomycin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
Related Drugs
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL262777. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 14969. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="vancomycin"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/vancomycin/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/vancomycin/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/vancomycin/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="vancomycin"></drugfyi-drug>